Platform
Business
Investors
Newsroom
Company
ENG
Platform
Business
Investors
Newsroom
Company
ENG
2020-Present
2020-NOW
Ushering in a New Era of AI Drug Development
2020-NOW
Ushering in a New Era of AI Drug Development
Ushering in a New Era of AI Drug Development
2025
2025
September
ABSC natural convention-based air circulation system patent registerd
June
June
Signed a drug development agreement with a U.S. animal pharmaceuticals company
Signed a drug development agreement with a U.S. animal pharmaceuticals company
May
May
Signed a joint service agreement with OCMS Bio for an integrated “One-Shot Screening” platform for ultra-fast antibody drug discovery
Signed a joint service agreement with OCMS Bio for an integrated “One-Shot Screening” platform for ultra-fast antibody drug discovery
Mar
Mar
Official global launch of LM-VS (Language Model Virtual Screening) service based on AI drug discovery language model
Official global launch of LM-VS (Language Model Virtual Screening) service based on AI drug discovery language model
Signed a $3.1M drug candidate development agreement with U.S. Pragma Biosciences
Signed a $3.1M drug candidate development agreement with U.S. Pragma Biosciences
Partnered with MSK to co-develop new anti-cancer drug compounds
Partnered with MSK to co-develop new anti-cancer drug compounds
Feb
Feb
Signed a joint research agreement with PDC*line Pharma for a neoantigen cancer vaccine
Signed a joint research agreement with PDC*line Pharma for a neoantigen cancer vaccine
Jan
Jan
Obtained Platinum grade certification for eco-friendly green data center at ABS Center
Obtained Platinum grade certification for eco-friendly green data center at ABS Center
2024
2024
Dec
Dec
Signed a DeepMatcher service provision agreement with RUDACURE
Signed a DeepMatcher service provision agreement with RUDACURE
Nov
Nov
Signed 1st service agreement with a US Nasdaq-listed TPD-specialized biotech
Signed 1st service agreement with a US Nasdaq-listed TPD-specialized biotech
Sep
Sep
Signed MOU with Enamine (Ukraine) for compound supply, synthesis, and collaborative AI drug discovery
Signed MOU with Enamine (Ukraine) for compound supply, synthesis, and collaborative AI drug discovery
2023
2023
Nov
Nov
Signed MOU with QIMR Berghofer Medical Research Institute (Australia) for joint drug development and commercialization
Signed MOU with QIMR Berghofer Medical Research Institute (Australia) for joint drug development and commercialization
Sep
Sep
Completed the AI Bio Supercomputing Center in Dungok, Daejeon
Completed the AI Bio Supercomputing Center in Dungok, Daejeon
Jul
Jul
Signed MOU with U.S. Metaclipse Therapeutics for joint research on personalized therapeutic cancer vaccines
Signed MOU with U.S. Metaclipse Therapeutics for joint research on personalized therapeutic cancer vaccines
2022
2022
Dec
Dec
Launched STB CLOUD service in the U.S.
Launched STB CLOUD service in the U.S.
2021
2021
Nov
Nov
Signed MOU with JW Pharmaceutical for innovative drug development
Signed MOU with JW Pharmaceutical for innovative drug development
Aug
Aug
Signed strategic MOU with KT to build an AI supercomputing center
Signed strategic MOU with KT to build an AI supercomputing center
Established Syntekabio USA, Inc. (New York)
Established Syntekabio USA, Inc. (New York)
Jan
Jan
Signed joint research agreement with Hanmi Science for COVID-19 drug repurposing
Signed joint research agreement with Hanmi Science for COVID-19 drug repurposing
2020
2020
Dec
Dec
Registered domestic patent for SARS-CoV-2 treatment composition
Registered domestic patent for SARS-CoV-2 treatment composition
Sep
Sep
Signed MOU with KIMCo, Naver Business Platform, and AI Center
Signed MOU with KIMCo, Naver Business Platform, and AI Center
Jun
Jun
Signed joint research agreement with KRIBB for COVID-19 drug repurposing
Signed joint research agreement with KRIBB for COVID-19 drug repurposing
Selected by the Ministry of Science and ICT as an excellent case in DNA (Data, Network, AI) innovation companies
Selected by the Ministry of Science and ICT as an excellent case in DNA (Data, Network, AI) innovation companies
2016–2019
2016–2019
Expansion into AI-based New Drug Development
2016–2019
Expansion into AI-based New Drug Development
Expansion into AI-based New Drug Development
2019
2019
Dec
Dec
Listed on KOSDAQ
Listed on KOSDAQ
Jun
Jun
Raised KRW 19.7 billion in Series C funding led by Yuhan Corporation, Sehan Venture Capital, and Timewise Investment
Raised KRW 19.7 billion in Series C funding led by Yuhan Corporation, Sehan Venture Capital, and Timewise Investment
Apr
Apr
Registered domestic patent for AI-based new drug development system
Registered domestic patent for AI-based new drug development system
Mar
Mar
Licensed-in an immune-oncology drug candidate co-discovered with CJ Healthcare
Licensed-in an immune-oncology drug candidate co-discovered with CJ Healthcare
2018
2018
Dec
Dec
Published a paper on integrated genomic core technology in BMC Bioinformatics 2018
Published a paper on integrated genomic core technology in BMC Bioinformatics 2018
Signed a collaboration agreement with Yonsei Severance Hospital Precision Medicine Center
Signed a collaboration agreement with Yonsei Severance Hospital Precision Medicine Center
Nov
Nov
Signed joint research agreement with JW Pharmaceutical for predictive biomarkers
Signed joint research agreement with JW Pharmaceutical for predictive biomarkers
Sep
Sep
Applied for domestic patent of AI-based new drug development system
Applied for domestic patent of AI-based new drug development system
Jun
Jun
Published proof-of-concept paper on deep learning-based drug development model CDRscan in Scientific Reports 2018
Published proof-of-concept paper on deep learning-based drug development model CDRscan in Scientific Reports 2018
Published validation paper on genetic mutation detection algorithm ADIscan in Nucleic Acids Research 2018
Published validation paper on genetic mutation detection algorithm ADIscan in Nucleic Acids Research 2018
May
May
Raised KRW 12 billion in Series B funding (Smilegate, KDB Industrial Bank, etc.)
Raised KRW 12 billion in Series B funding (Smilegate, KDB Industrial Bank, etc.)
Signed a cooperation agreement with Inha University Hospital for cancer-related medical centers
Signed a cooperation agreement with Inha University Hospital for cancer-related medical centers
Apr
Apr
Signed joint research and cooperation MOU with Yuhan Corporation
Signed joint research and cooperation MOU with Yuhan Corporation
2017
2017
Dec
Dec
Signed research agreement with CJ Healthcare for discovery of drug active compounds
Signed research agreement with CJ Healthcare for discovery of drug active compounds
Nov
Nov
Signed joint research MOU with Yonsei Severance Hospital
Signed joint research MOU with Yonsei Severance Hospital
Aug
Aug
Registered domestic patent for bio big data analysis method
Registered domestic patent for bio big data analysis method
Published clinical validation paper on NGS testing for rare diseases in Scientific Reports 201
Published clinical validation paper on NGS testing for rare diseases in Scientific Reports 201
Jun
Jun
Obtained GMP certification from the Ministry of Food and Drug Safety (KTC-CAB-179288)
Obtained GMP certification from the Ministry of Food and Drug Safety (KTC-CAB-179288)
Mar
Mar
Published validation paper on HLAscan accuracy in BMC Bioinformatics 2017
Published validation paper on HLAscan accuracy in BMC Bioinformatics 2017
2016
2016
Nov
Nov
Selected as an Excellent AI Company by the Ministry of Science and ICT
Selected as an Excellent AI Company by the Ministry of Science and ICT
Jun
Jun
Obtained “New Health Technology Certification” for genetic disease screening
Obtained “New Health Technology Certification” for genetic disease screening
Raised KRW 6 billion in Series A funding (Altos Ventures, etc.)
Raised KRW 6 billion in Series A funding (Altos Ventures, etc.)
May
May
Awarded “Outstanding Company” at the Korea Biotechnology Awards
Awarded “Outstanding Company” at the Korea Biotechnology Awards
Jan
Jan
Registered as a genetic testing institution with the Korea Disease Control and Prevention Agency
Registered as a genetic testing institution with the Korea Disease Control and Prevention Agency
2009-2015
2009-2015
Foundation and Accumulation of Core Technology
2009-2015
Foundation and Accumulation of Core Technology
Foundation and Accumulation of Core Technology
2015
2015
Nov
Nov
Obtained approval from the Ministry of Food and Drug Safety to introduce Dx NGS equipment
Obtained approval from the Ministry of Food and Drug Safety to introduce Dx NGS equipment
May
May
Registered domestic patent for personalized neo-antigen prediction algorithm
Registered domestic patent for personalized neo-antigen prediction algorithm
Feb
Feb
Completed beta version of PMAP (Personal Genome Map) automatic generation
Completed beta version of PMAP (Personal Genome Map) automatic generation
2014
2014
Oct
Oct
Registered domestic patent for personalized cancer vaccine system
Registered domestic patent for personalized cancer vaccine system
Apr
Apr
Selected as a laboratory company by the Electronics and Telecommunications Research Institute (ETRI)
Selected as a laboratory company by the Electronics and Telecommunications Research Institute (ETRI)
Mar
Mar
Registered international patent (WO) for anticancer drug response prediction algorithm
Registered international patent (WO) for anticancer drug response prediction algorithm
2013
2013
Dec
Dec
Selected as one of the “Top 100 Future Technologies and Leaders for 2020”
Selected as one of the “Top 100 Future Technologies and Leaders for 2020”
Sep
Sep
Registered international patent (WO) for genetic mutation-based anticancer drug efficacy prediction
Registered international patent (WO) for genetic mutation-based anticancer drug efficacy prediction
Apr
Apr
Decision to register RVR DBMS/search system with the U.S. Patent and Trademark Office
Decision to register RVR DBMS/search system with the U.S. Patent and Trademark Office
2012
2012
Jul
Jul
Registered domestic patent for bio big data-based personalized medicine platform
Registered domestic patent for bio big data-based personalized medicine platform
Feb
Feb
Completed genome analysis platform (NGS-pL)
Completed genome analysis platform (NGS-pL)
Jan
Jan
Launched integrated genome service for next-generation personalized medicine genome project
Launched integrated genome service for next-generation personalized medicine genome project
2011
2011
Dec
Dec
Registered domestic patent for pharmacogenomics-based anticancer drug response prediction
Registered domestic patent for pharmacogenomics-based anticancer drug response prediction
Jun
Jun
Registered domestic patent for HLA typing method using genome data
Registered domestic patent for HLA typing method using genome data
2010
2010
Aug
Aug
Registered domestic patent for pharmacogenomics algorithm
Registered domestic patent for pharmacogenomics algorithm
2009
2009
Oct
Oct
Syntekabio, Inc. founded
Syntekabio, Inc. founded
Global Premier AI
Drug Partner
Innovate with us.
Contact Us
Contact Us
© Syntekabio Co., Ltd. All rights reserved.
General Inquiries
Investor Relations / Press
Business Development / Partnerships
Data Center
Family Sites
© Syntekabio Co., Ltd. All rights reserved.